Sawsan As‐Sanie

ORCID: 0000-0002-7166-1979 · 87 papers in corpus · active 2004-2025

Study types

  • article 69
  • review 13
  • book-chapter 2
  • letter 2
  • other 1

Condition tags

  • endometriosis 53
  • chronic_pelvic_pain 30
  • mesh:D004715 26
  • mesh:D017699 20
  • dysmenorrhea 9
  • mesh:D004412 6
  • dyspareunia 6
  • mesh:D004414 3
  • irritable_bowel_syndrome 1
  • interstitial_cystitis 1
other 2025
Does interdisciplinary group care for the treatment of endometriosis improve pain interference: protocol for a pilot randomised controlled trial at an urban academic medical centre
BMJ open ·doi:10.1136/bmjopen-2024-097372

INTRODUCTION: Endometriosis affects 10-15% of people assigned female at birth and can cause chronic pelvic pain and impair many domains of quality of life, such as fertility, mood and bladder, bowel and sexual function. Current treatments o…

review 2025
Endometriosis
JAMA ·doi:10.1001/jama.2025.2975

Importance: Endometriosis is a chronic, estrogen-dependent, inflammatory disease defined by endometrial-like tissue (lesions) outside the uterine lining. It affects up to 10% of women worldwide, and 9 million women in the US, during reprodu…

review 2025
Female Dyspareunia and the Relationship to Neurophysiologic Mechanisms: A Scoping Review
Journal of minimally invasive gynecology ·doi:10.1016/j.jmig.2025.07.018

OBJECTIVE: This scoping review aims to evaluate recent studies that examine the relationship between dyspareunia and neurophysiologic factors, and to synthesize their results as it pertains to the development and treatment of introital/vulv…

article 2025
Impacts of Childhood Chronic Pain on Adulthood Pelvic Pain
·doi:10.1016/j.jmig.2025.09.052
letter 2024
From Dismissal to Solutions
·doi:10.1097/aog.0000000000005639
article 2024
Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study
Human Reproduction ·doi:10.1093/humrep/dead263

STUDY QUESTION: What is the efficacy and safety of long-term treatment (up to 2 years) with relugolix combination therapy (CT) in women with moderate to severe endometriosis-associated pain? SUMMARY ANSWER: For up to 2 years, treatment with…

article 2024
World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization Project: V. Physical examination standards in endometriosis research
Fertility and sterility ·doi:10.1016/j.fertnstert.2024.03.007

OBJECTIVE: The World Endometriosis Research Foundation established the Endometriosis Phenome and Biobanking Harmonisation Project (EPHect) to create standardized documentation tools (with common data elements) to facilitate the comparison a…

article 2023
A Plain Language Summary to Learn About Relugolix Combination Therapy for the Treatment of Pain Associated with Endometriosis
Pain management ·doi:10.2217/pmt-2023-0052

WHAT IS THIS SUMMARY ABOUT?: This is a summary of research studies (known as clinical trials) called SPIRIT 1 and SPIRIT 2. The SPIRIT 1 and SPIRIT 2 studies compared how well a medicine called relugolix combination therapy worked in reliev…

article 2023
Association Between Nociplastic Pain and Pain Severity and Impact in Women With Chronic Pelvic Pain
The journal of pain ·doi:10.1016/j.jpain.2023.03.004
article 2023
Bleeding Patterns With Relugolix Combination Therapy in Women With Endometriosis-Associated Pain [ID: 1345374]
·doi:10.1097/01.aog.0000929844.43483.20

INTRODUCTION: Relugolix combination therapy (Relugolix-CT: relugolix 40 mg, estradiol 1 mg, norethindrone acetate 0.5 mg) significantly improved endometriosis-associated pain versus placebo in the SPIRIT 1&2 studies. Efficacy was maintained…

article 2023
Impact of Time Since Surgical Diagnosis of Endometriosis on Outcomes with Relugolix Combination Therapy: Spirit Long-Term Extension (LTE)
·doi:10.1016/j.jmig.2023.08.031
article 2023
Neurotrophins and Their Receptors, Novel Therapeutic Targets for Pelvic Pain in Endometriosis, Are Coordinately Regulated by IL-1β via the JNK Signaling Pathway
The American journal of pathology ·doi:10.1016/j.ajpath.2023.04.007
article 2023
O-032 Effect of relugolix combination therapy in women with endometriosis-associated pain who received prior first-line hormonal treatment: SPIRIT 1 and 2
·doi:10.1093/humrep/dead093.032

Abstract Study question To assess the effect of oral relugolix combination therapy (Relugolix-CT) in the subgroup of women with endometriosis-associated pain who received prior first-line hormonal treatment. Summary answer Relugolix-CT sign…

article 2023
Predictors of Interest in Surgical Management for Chronic Pelvic Pain
·doi:10.1016/j.jmig.2023.08.069
article 2022
70 Effects of relugolix combination therapy on endometriosis-associated pain and analgesic use in spirit studies: overall study and european populations
·doi:10.1016/j.ejogrb.2021.11.131
article 2022
Impact of endometriosis on women’s life decisions and goal attainment: a cross-sectional survey of members of an online patient community
BMJ open ·doi:10.1136/bmjopen-2021-052765

OBJECTIVES: To examine women's perceptions of endometriosis-associated disease burden and its impact on life decisions and goal attainment. DESIGN: An anonymous online survey was distributed in October 2018 through the social media network …

article 2022
Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2)
Lancet (London, England) ·doi:10.1016/s0140-6736(22)00622-5

BACKGROUND: Endometriosis is a common cause of pelvic pain in women, for which current treatment options are suboptimal. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, combined with estradiol and a progestin, was eva…

article 2022
Racial disparities in the prevalence of endometriosis in patients undergoing abdominal or laparoscopic hysterectomy
·doi:10.1016/j.ajog.2021.12.092
article 2022
Trends in pelvic pain symptoms over 2 years of follow-up among adolescents and young adults with and without endometriosis
Pain ·doi:10.1097/j.pain.0000000000002747

ABSTRACT: We described trends in pelvic pain characteristics over 2 years of follow-up among adolescents and adults with and without endometriosis participating in the longitudinal observational cohort of the Women's Health Study: From Adol…

article 2021
02 Incidence and predictors of persistent pelvic pain following hysterectomy in women with chronic pelvic pain
·doi:10.1016/j.ajog.2021.04.026
article 2021
ASSESSMENT OF COMMON ADVERSE EVENTS OF RELUGOLIX COMBINATION THERAPY IN PREMENOPAUSAL WOMEN TREATED FOR SYMPTOMATIC ESTROGEN-DRIVEN CONDITIONS: LIBERTY AND SPIRIT STUDIES
·doi:10.1016/j.fertnstert.2021.07.038
article 2021
Cannabidiol Use, Substitution for Medications, and Perceptions of Effectiveness in Women with Chronic Pelvic Pain
·doi:10.1016/j.jmig.2021.09.475
article 2021
Development of a visual, patient-reported tool for assessing the multi-dimensional burden of endometriosis
Current medical research and opinion ·doi:10.1080/03007995.2021.1929896

OBJECTIVE: Inadequate communication about endometriosis symptom burden between women and healthcare providers is a barrier for optimal treatment. This study describes the development of the EndoWheel, a patient-reported assessment tool that…

article 2021
Incidence and predictors of persistent pelvic pain following hysterectomy in women with chronic pelvic pain
American journal of obstetrics and gynecology ·doi:10.1016/j.ajog.2021.08.038
article 2021
O-131 The effect of time since surgical diagnosis of endometriosis on treatment outcomes with relugolix combination therapy in women with endometriosis-associated pain: SPIRIT program
·doi:10.1093/humrep/deab126.056

Abstract Study question To assess the efficacy of Relugolix-CT vs placebo in women who were surgically diagnosed with endometriosis <5 and > = 5 years ago. Summary answer Treatment outcomes did not differ for dysmenorrhea and daily fu…